Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1989 15
1990 58
1991 49
1992 58
1993 56
1994 42
1995 31
1996 38
1997 42
1998 33
1999 26
2000 29
2001 33
2002 21
2003 42
2004 15
2005 24
2006 24
2007 16
2008 15
2009 9
2010 13
2011 21
2012 8
2013 15
2014 17
2015 17
2016 23
2017 30
2018 30
2019 26
2020 23
2021 22
2022 23
2023 24
2024 20
2025 28
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

983 results

Results by year

Filters applied: . Clear all
Page 1
Anti-MAG neuropathy: From biology to clinical management.
Steck AJ. Steck AJ. J Neuroimmunol. 2021 Dec 15;361:577725. doi: 10.1016/j.jneuroim.2021.577725. Epub 2021 Sep 28. J Neuroimmunol. 2021. PMID: 34610502 Free article. Review.
The initial use of chemotherapeutic agents was replaced by the introduction in the late 1990s of rituximab, a monoclonal antibody against CD20(+) B-cells. Since then, other anti-B cells agents have been introduced. Recently a novel antigen-specific immunotherapy neutralizi …
The initial use of chemotherapeutic agents was replaced by the introduction in the late 1990s of rituximab, a monoclonal antibody aga …
CD57.
Warren HS. Warren HS. J Biol Regul Homeost Agents. 2000 Oct-Dec;14(4):322-3. J Biol Regul Homeost Agents. 2000. PMID: 11215830 No abstract available.
NKG2C and NKG2A coexpression defines a highly functional antiviral NK population in spontaneous HIV control.
Sánchez-Gaona N, Gallego-Cortés A, Astorga-Gamaza A, Rallón N, Benito JM, Ruiz-Mateos E, Curran A, Burgos J, Navarro J, Suanzes P, Falcó V, Genescà M, Buzon MJ. Sánchez-Gaona N, et al. JCI Insight. 2024 Sep 17;9(20):e182660. doi: 10.1172/jci.insight.182660. JCI Insight. 2024. PMID: 39288262 Free PMC article.
Phenotypic profiling of NK cells revealed profound differences compared with other PWH, but marked similarities to uninfected individuals, with a distinctive prevalence of NKG2C+CD57+ memory-like NK cells. Functional analyses indicated that ECs had limited production of fu …
Phenotypic profiling of NK cells revealed profound differences compared with other PWH, but marked similarities to uninfected individuals, w …
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P, Adeniji OS, Bordoloi D, Kinslow J, Martinson J, Parent DM, Hong KY, Koshy J, Kulkarni AJ, Zilberstein NF, Balk RA, Moy JN, Giron LB, Tracy RP, Keshavarzian A, Muthumani K, Landay A, Weiner DB, Abdel-Mohsen M. Saini P, et al. mBio. 2023 Feb 28;14(1):e0339322. doi: 10.1128/mbio.03393-22. Epub 2023 Feb 2. mBio. 2023. PMID: 36728420 Free PMC article.
We found that NK cells from hospitalized COVID-19 patients degranulate less against SARS-CoV-2 antigen-expressing cells (in direct cytolytic and antibody-dependent cell cytotoxicity [ADCC] assays) than NK cells from mild COVID-19 patients or negative controls. ...Consisten …
We found that NK cells from hospitalized COVID-19 patients degranulate less against SARS-CoV-2 antigen-expressing cells (in direct cytolytic …
Establishment and usefulness of an anti-human CD57 IgG1 monoclonal antibody.
Tajima J, Heike Y, Kato K, Ikarashi Y, Asada-Mikami R, Yoshida M, Kasahara T, Wakasugi H. Tajima J, et al. Immunol Lett. 2000 Jun 1;72(3):159-62. doi: 10.1016/s0165-2478(00)00190-5. Immunol Lett. 2000. PMID: 10880835
In the present study we established a new monoclonal antibody, JNK-1, which recognizes all cells recognized by CD57/HNK-1 mAb. JNK-1 and CD57 mAbs inhibited the binding of each other, suggesting that the molecules they recognize are either identical or suffic …
In the present study we established a new monoclonal antibody, JNK-1, which recognizes all cells recognized by CD57/HNK-1 mAb. …
Increased frequencies of CD8(+)CD57(+) T cells are associated with antibody neutralization breadth against HIV in viraemic controllers.
Palmer CD, Romero-Tejeda M, Scully EP, Lockhart A, Seaman MS, Goldenthal A, Piechocka-Trocha A, Walker BD, Chibnik LB, Jost S, Porichis F. Palmer CD, et al. J Int AIDS Soc. 2016 Dec 9;19(1):21136. doi: 10.7448/IAS.19.1.21136. eCollection 2016. J Int AIDS Soc. 2016. PMID: 27938646 Free PMC article.
INTRODUCTION: An effective prophylactic vaccine against HIV will need to elicit antibody responses capable of recognizing and neutralizing rapidly evolving antigenic regions. The immunologic milieu associated with development of neutralizing antibody breadth remains …
INTRODUCTION: An effective prophylactic vaccine against HIV will need to elicit antibody responses capable of recognizing and neutral …
CD56(+)CD57(+) infiltrates as the most predominant subset of intragraft natural killer cells in renal transplant biopsies with antibody-mediated rejection.
Jung HR, Kim MJ, Wee YM, Kim JY, Choi MY, Choi JY, Kwon H, Jung JH, Cho YM, Go H, Kim SY, Ryu YM, Kim YJ, Kim YH, Han DJ, Shin S. Jung HR, et al. Sci Rep. 2019 Nov 12;9(1):16606. doi: 10.1038/s41598-019-52864-5. Sci Rep. 2019. PMID: 31719573 Free PMC article.
According to histopathologic reports, 8 patients (20.5%) had no rejection (NR), 11 (28.2%) had T cell-mediated rejections (TCMR) only, and 20 (51.3%) had antibody-mediated rejection (ABMR). NK cells were defined as CD3(-)CD56(+) lymphocytes that are positive for CD57 …
According to histopathologic reports, 8 patients (20.5%) had no rejection (NR), 11 (28.2%) had T cell-mediated rejections (TCMR) only, and 2 …
Specificity of antiglycolipid antibodies.
Baumann N. Baumann N. Clin Rev Allergy Immunol. 2000 Aug;19(1):31-40. doi: 10.1385/CRIAI:19:1:31. Clin Rev Allergy Immunol. 2000. PMID: 11064824 Review. No abstract available.
CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection.
Espinosa J, Herr F, Tharp G, Bosinger S, Song M, Farris AB 3rd, George R, Cheeseman J, Stempora L, Townsend R, Durrbach A, Kirk AD. Espinosa J, et al. Am J Transplant. 2016 Apr;16(4):1102-12. doi: 10.1111/ajt.13613. Epub 2016 Jan 14. Am J Transplant. 2016. PMID: 26603381 Free PMC article.
Contrary to data recognizing CD57 as a marker of senescence on CD8 T cells, we discovered a nonsenescent, cytolytic phenotype associated with CD57 on CD4 T cells. ...These data implicate CD57(+) CD4 T cells in clinical CoBRR. If prospectively validated, this …
Contrary to data recognizing CD57 as a marker of senescence on CD8 T cells, we discovered a nonsenescent, cytolytic phenotype associa …
CD94-driven in vitro expansion of highly functional adaptive NKG2C(+) NKG2A(-) CD57(+) NK cells from CMV(+) healthy donors.
Giordano C, Carlomagno S, Falco M, Cantoni C, Vitale M, Caruana I, Dirks J, Serio A, Muccio L, Bartalucci G, Bo A, Locatelli F, Bottino C, Sivori S, Della Chiesa M. Giordano C, et al. Front Immunol. 2025 Jan 31;16:1481745. doi: 10.3389/fimmu.2025.1481745. eCollection 2025. Front Immunol. 2025. PMID: 39958331 Free PMC article.
They are characterized by CD94/NKG2C expression, a mature CD57(+)KIR(+)NKG2A(-) phenotype, a prolonged lifespan, and remarkable antitumor functions. ...The method is based on the use of an anti-CD94 monoclonal antibody (mAb) combined with IL-2 or IL-15. RESULTS: By …
They are characterized by CD94/NKG2C expression, a mature CD57(+)KIR(+)NKG2A(-) phenotype, a prolonged lifespan, and remarkable antit …
983 results